The development of Cassava Sciences’ (SAVA) Alzheimer treatment appears to be rolling along smoothly. On Monday, the biotech said its End-of Phase 2 (EOP2) mid-January meeting with the FDA had gone well. The company met up with the regulatory body to discuss the path forward for simufilam, Cassava’s Alzheimer’s disease (AD) drug candidate, which is now ready for a Phase 3 trial. After speaking with management, H.C.